Document is current
Any future updates will be listed below
-
Authors
Hu, Wei http://orcid.org/0000-0002-0392-6939
Wang, Zhong-Min http://orcid.org/0000-0002-5538-1969
Feng, Yongqiang http://orcid.org/0000-0002-2320-5063
Schizas, Michail
Hoyos, Beatrice E.
van der Veeken, Joris
Verter, Jacob G. http://orcid.org/0000-0003-3710-6549
Bou-Puerto, Regina http://orcid.org/0000-0002-7546-3312
Rudensky, Alexander Y. http://orcid.org/0000-0003-1280-2898
-
Funding
Funding for this research was provided by:
Ludwig Institute for Cancer Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA08748)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI034206)
Howard Hughes Medical Institute
Parker Institute for Cancer Immunotherapy
Cancer Research Institute
W. H. is supported by an Irvington-Cancer Research Institute Postdoctoral Fellowship.
Z.-M.W. is supported by a Bruce Charles Forbes Fellowship.
-
License Information
Text and Data Mining valid from 2021-08-23
Version of Record valid from 2021-08-23
-
More Information
Article History
Received: 22 January 2021
Accepted: 14 July 2021
First Online: 23 August 2021
Competing interests
: A.Y.R. is a co-founder and Science Advisory Board member of and holds stock options in Vedanta Bioscience and Sonoma Biotherapeutics. The other authors declare no competing interests.
